Strategic Acquisition Neuravi is now part of the Johnson & Johnson family through Codman Neuro's acquisition in 2017, indicating strong backing and integration potential for expanded distribution of its EmboTrap II device across larger medical networks.

European Market Ready EmboTrap II is CE marked and commercially available in Europe, presenting a ready-to-sell asset for EU hospital systems, stroke centers, and procurement teams seeking validated neurovascular solutions.

Limited US Access Device has investigational use status in the United States, signaling a near-term opportunity for strategic partnerships or clinical programs to facilitate eventual regulatory approval and market entry.

Clinical Collaboration Active engagement through the Neuravi Thromboembolic Initiative demonstrates a commitment to research partnerships, offering a pathway to co-develop trials, gather real-world data, and strengthen value propositions for health systems.

Small Team, Focused Value With a lean team and substantial backing ($17M in funding) alongside potential alignment with larger device ecosystems, there is opportunity to partner with larger distributors, OEMs, or partners in neurology/neurointerventional channels to accelerate adoption.